Gottlieb talked up the prospect of releasing redacted CRLs in his confirmation hearings but has now watered down his interest in the idea.

The pact sets Merck up to work with researchers at CRUK’s unit at the ICR on three preclinical oncology projects.

We catch up with Doug Ingram, chief at rare disease biotech Sarepta, and discuss how he aims to remove the term “controversial” in front of the company’s name.

AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) as it plays catch-up with Biogen and Ionis.

The €8.7 million series B will support studies targeting two bacterial infections and the creation of a drug manufacturing unit.

Describing a country as a ‘shithole’ isn’t going to endear you to anyone, but President Trump’s latest alleged outburst has struck a nerve with one particular…

Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when the company's generic drug unit is suffering.

The deal follows the biopharma industry's growing interest in immuno-oncology.

The German company is seeking $22 million to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer.